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Abstract
 
Mucosal organs such as the intestine are supported by a rich and complex underlying vascula-
ture. For this reason, the intestine, and particularly barrier-protective epithelial cells, are sus-
ceptible to damage related to diminished blood flow and concomitant tissue hypoxia. We
sought to identify compensatory mechanisms that protect epithelial barrier during episodes of
intestinal hypoxia. Initial studies examining T84 colonic epithelial cells revealed that barrier
function is uniquely resistant to changes elicited by hypoxia. A search for intestinal-specific,
barrier-protective factors revealed that the human intestinal trefoil factor (ITF) gene promoter
bears a previously unappreciated binding site for hypoxia-inducible factor (HIF)-1. Hypoxia
resulted in parallel induction of ITF mRNA and protein. Electrophoretic mobility shift assay
analysis using ITF-specific, HIF-1 consensus motifs resulted in a hypoxia-inducible DNA bind-
ing activity, and loading cells with antisense oligonucleotides directed against the 
 
a
 
 chain of
HIF-1 resulted in a loss of ITF hypoxia inducibility. Moreover, addition of anti-ITF antibody
resulted in a loss of barrier function in epithelial cells exposed to hypoxia, and the addition of
recombinant human ITF to vascular endothelial cells partially protected endothelial cells from
hypoxia-elicited barrier disruption. Extensions of these studies in vivo revealed prominent hy-
poxia-elicited increases in intestinal permeability in ITF null mice. HIF-1–dependent induc-
tion of ITF may provide an adaptive link for maintenance of barrier function during hypoxia.
Key words: epithelium • gastrointestinal disease • transcription factor • intestinal permeability • 
endothelium
 
Introduction
 
Epithelial cells are anatomically positioned to provide a
barrier to antigenic flux and luminal bacteria (1). Mucosal
organs, such as the intestine, rely on an extensive underly-
ing vasculature, and therefore are primary sites for condi-
tions of diminished blood flow and resultant tissue hypoxia
(2). Under such conditions, maintenance of barrier func-
tion depends on structures within the intercellular tight
junction at the boundary of the apical and basolateral mem-
brane domain. At present, it is not known if protective
mechanisms exist to support functional epithelial barrier
properties during episodes of diminished blood flow and
resultant hypoxia.
Both adaptive (e.g., erythropoietin [EPO],
 
1
 
 glycolytic
 
enzymes) and proinflammatory (e.g., TNF-
 
a
 
, IL-8) re-
sponses have been attributed to conditions of diminished
tissue oxygen delivery (hypoxia), and it is now clear that re-
sponses to hypoxia include transcriptionally regulated gene
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Abbreviations used in this paper:
 
 EMSA, electrophoretic mobility shift assay;
EPO, erythropoietin; HIF, hypoxia-inducible factor; HRE, hypoxic re-
sponse element; ITF, intestinal trefoil factor; MDCK, Madin-Darby canine
kidney; MVEC, microvascular endothelial cell; RT, reverse transcription. 
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expression
 
 
 
(2, 3). One such transcriptional pathway relies
on the activation of hypoxia-inducible factor (HIF)-1, a
member of the rapidly growing per-ARNT-sim family of
basic helix-loop-helix (bHLH) transcription factors (4–6).
Functional HIF-1 exists as an 
 
ab
 
 heterodimer, the activa-
tion of which is dependent on stabilization of an O
 
2
 
-depen-
dent degradation pathway (7)
 
.
 
 Binding of HIF-1 to DNA
consensus domains (5
 
9
 
-RCGTG-3
 
9
 
) results in the transcrip-
tional induction of HIF-1–bearing gene promoters
 
 
 
(3).
HIF-1 is widely expressed and recent studies indicate that
consensus HIF-1–binding sequences exist in a number of
genes (3). Here we demonstrate that hypoxia induces the
epithelial-specific, barrier-protective protein intestinal tre-
foil factor (ITF) through an HIF-1–dependent mechanism.
 
Materials and Methods
 
Growth and Maintenance of Cell Lines.
 
T84 cells and a sub-
clone of Caco-2 B Be cells with high epithelial resistance were
grown as monolayers on polycarbonate permeable supports as de-
scribed previously (8, 9). The KB cell line is a human oral epithe-
lial cell line derived from native human mucosa (10). Human mi-
crovascular endothelial cells (MVECs) are primary culture
endothelial cells (Cascade Biologics, Inc.) derived from the hu-
man dermis and were cultured as described previously (11). Ma-
din-Darby canine kidney (MDCK) cells were cultured and pas-
saged as described previously (12). Confluent cells were exposed
to hypoxia in a humidified hypoxic cell chamber (Coy Labora-
tory Products, Inc.) as described previously
 
 
 
(13). Standard hy-
poxic conditions (based on previous work; references 13–15)
were pO
 
2
 
 
 
5 
 
20 Torr, pCO
 
2
 
 
 
5 
 
35 Torr, with the balance made
up of nitrogen and water vapor. Normoxic controls were cells
exposed to the same experimental protocols under conditions of
atmospheric oxygen concentrations (pO
 
2
 
 
 
5
 
 147 Torr and pCO
 
2
 
 
 
5
 
35 Torr within a tissue culture incubator). Paracellular permeabil-
ity was assessed as described previously (11) using FITC-labeled
dextran (40 kD).
 
Transcriptional Analysis.
 
The transcriptional profile of epithe-
lial cells exposed to ambient hypoxia was assessed in RNA de-
rived from control or hypoxic epithelia (T84 cells at 6- or 18-h
hypoxia) using quantitative gene chip expression arrays (Affyme-
trix, Inc.; reference 16). Reverse transcription (RT)-PCR analy-
sis of mRNA levels was performed using DNase-treated total
RNA as described previously (14)
 
 
 
using primers specific for hu-
man ITF (17) resulting in a 108-bp fragment or 
 
b
 
-actin (14) re-
sulting in a 661-bp fragment. In subsets of experiments, the tran-
scription inhibitor actinomycin D (10 ng/ml final concentration)
was used to determine the prevalence of newly synthesized RNA
in this response.
 
Western Blot Analysis.
 
After experimental treatment of epi-
thelial cells, cell culture supernatants (for examination of soluble
ITF) were prepared as described previously (11). Nuclear extracts
(for analysis of HIF-1
 
a
 
) were isolated from confluent monolayers
of epithelia on 100-mm petri dishes as described before (18).
Samples (25 
 
m
 
g/lane) were resolved by reducing SDS-PAGE,
transferred to nitrocellulose, and blocked overnight in blocking
buffer (250 mM NaCl, 0.02% Tween 20, 5% goat serum, 3%
BSA). For Western blotting, affinity-purified anti–HIF-1
 
a
 
 (gen-
erated by immunizing rabbits with an antigenic peptide encoded
in the HIF-1
 
a
 
 protein structure encoding amino acids 527–541
[MVNEFKLELVEKLFA] of HIF-1
 
a
 
) or anti-ITF (19) was added
 
for 3 h, blots were washed, and species-matched peroxidase-con-
jugated secondary Ab is added, as described previously (14). La-
beled bands from washed blots were detected by enhanced
chemiluminescence (Amersham Pharmacia Biotech).
 
Electrophoretic Mobility Shift Assay.
 
Nuclear extracts of cells
exposed to indicated experimental conditions were obtained as
described elsewhere. Synthetic oligonucleotides were synthe-
sized (Genosys Biotechnologies, Inc.) and used as probes in elec-
trophoretic mobility shift assays (EMSAs). The hypoxic response
element (HRE) motif lies at 
 
2
 
129 to 
 
2
 
122 relative to the tran-
scription start site in the ITF promoter
 
 
 
(17). Oligonucleotide
probes for EMSA were digoxigenin-labeled, incubated with nu-
clear lysates, and resolved on a 6% nondenaturing polyacrylamide
gel as described previously (Boehringer; reference 14). DNA–
protein complexes were transblotted to nylon membrane,
probed with antidigoxigenin-peroxidase, and developed by en-
hanced chemiluminescence. Controls consisted of free probe
alone, excess unlabeled probe, or a species-matched irrelevant
Ab (anti-cAMP response element–binding protein [CREB];
Transduction Labs, Inc.).
 
HIF-1
 
a
 
 Antisense Oligonucleotide Treatment.
 
HIF-1
 
a
 
 deple-
tion in epithelial cells was accomplished by using antisense oligo-
nucleotide loading as described previously (20) using phosphor-
othioate derivatives of antisense (GCC GGC GCC CTC CAT)
or control sense (ATG GAG GGC GCC GGC) oligonucle-
otides. T84 epithelial cells were washed in serum free media,
then in media containing 20 
 
m
 
g/ml effectene transfection reagent
(QIAGEN) with 2 
 
m
 
g/ml HIF-1
 
a
 
 antisense or sense oligonucle-
otide. Cells were incubated for 4 h at 37
 
8
 
C and then replaced
with serum containing growth media. Treated cells were exposed
to hypoxia or normoxia for indicated periods of time. As indi-
cated, ITF mRNA was quantified by RT-PCR as described
above (see Transcriptional Analysis).
 
HIF-1 Transfection.
 
Stable cell lines overexpressing HIF-1
 
a
 
(plasmid provided by H.F. Bunn, Harvard Medical School; refer-
ence 7) were generated in the high resistance Caco-2 B Be cell
line as described previously
 
 
 
(8). Primary screening for HIF-1 ex-
pression was by RT-PCR analysis. Clones with the highest ex-
pression underwent secondary screens based on electrophysio-
logic characteristics (high resistance monolayers) and Western
blot analysis of HIF-1
 
a
 
.
 
Intestinal Permeability In Vivo.
 
The generation of ITF null
mice has been described previously (21). Intestinal permeability
was examined in 6–10-wk-old wild-type Bl6129 (Taconic, Inc.)
or ITF null mice using an FITC-labeled dextran method as de-
scribed previously (22). Mice were gavaged with 60 mg/100 g
body weight of FITC-dextran (4,000 kD at 80 mg/ml; Sigma-
Aldrich) and exposed to ambient hypoxia (8% O
 
2
 
, 92% N
 
2
 
) or
ambient room air for various times (
 
n 
 
= 4–6 per condition). In
some experiments, mice were administered either recombinant
human ITF (30 mg/kg, 75% gastric lavage, 25% enema) or PBS 1 h
before hypoxia. Cardiac puncture was performed and serum anal-
ysis of FITC concentration performed. In subsets of experiments,
tissues were collected from wild-type and ITF null mice after hy-
poxia and fixed in 10% buffered formalin. 5-
 
m
 
m sections were
cut, stained with hematoxylin and eosin, and histologically char-
acterized. Colonic tissue was harvested and homogenized and
RNA extracted with Trizol as described above. Another section
of colonic mucosal scrapings was harvested and processed for
Western blot analysis as described above. This protocol was in ac-
cordance with National Institutes of Health guidelines for use of
live animals and was approved by the Institutional Animal Care
and Use Committee at Brigham and Women’s Hospital. 
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Statistical Analyses.
 
ITF bioactivity and paracellular perme-
ability data were compared by one- or two-factor analysis of vari-
ance or by Student’s 
 
t
 
 test where appropriate. Values are ex-
pressed as the mean and SEM from at least three separate
experiments.
 
Results
 
Colonic Epithelia Resist Hypoxia-elicited Barrier Changes.
 
Previous reports indicate that colonic epithelial barrier
function is maintained during even severe conditions of
hypoxia (13, 14). In contrast, other cell types (e.g., vascular
endothelia) appear to markedly lose barrier qualities during
ambient hypoxia (23). As shown in Table I, comparison of
six barrier cell types revealed that colonic epithelial cells
(T84 and Caco-2 cells), as opposed to other epithelia (KB,
A549, and MDCK) or MVECs, appear to be uniquely re-
sistant to increased permeability induced by hypoxia, sug-
gesting that intestinal epithelial cells possess mechanisms
that sustain barrier function under such conditions.
 
Hypoxia Induces ITF Production.
 
Transcriptional profil-
ing has been used to identify potential factors contributing
to maintenance of barrier during hypoxia (24, 25). Microar-
ray analysis (26) was adopted to broadly screen hypoxia-
regulated genes in RNA derived from intestinal epithelia
(T84 cells), and identified a time-dependent induction of
the intestinal-specific, barrier-protective ITF gene (2.8- and
4.2-fold increase over control normoxia at 6- and 18-h hy-
poxia, respectively). Subsequently, RT-PCR analysis was
employed to corroborate results of microarray screening
(Fig. 1 a). This analysis of Caco-2 cells demonstrated a
time-dependent induction of ITF mRNA expression, and
was evident by 4-h exposure to hypoxia. Similar results
were seen in T84 cells (data not shown). Epithelial expo-
sure to the RNA synthesis inhibitor actinomycin D blocked
this hypoxia-elicited ITF induction (Fig. 1 b), indicating
that this response reflects new transcriptional activity. To
 
Table I.
 
Intestinal Epithelia Resist Hypoxia-elicited Disruption
 
Paracellular flux
Cell type Normoxia Hypoxia Fold increase
 
P
 
 value
 
pM/cm
 
2
 
/h pM/cm
 
2
 
/h
 
Epithelia
(T84, colon) 5 
 
6
 
 0.4 5 
 
6
 
 0.3 0.0 NS
Epithelia
(Caco-2, colon) 8 
 
6
 
 1.6 9 
 
6
 
 0.8 0.1 NS
Epithelia
(KB, oral) 97 
 
6 
 
8.1 430 
 
6
 
 12.6 4.4
 
,
 
0.001
Epithelia
(MDCK, kidney) 63 
 
6 
 
10.4 245 
 
6
 
 12.2 3.8
 
,
 
0.001
Epithelia
(A549, lung) 197 
 
6 
 
19.5 482 
 
6
 
 52.5 2.4
 
,
 
0.007
Epithelia
(MVEC, dermis) 127 
 
6
 
 5.1 395 
 
6 
 
14.6 3.1
 
,
 
0.001
Monolayers of indicated cell type were grown to confluence on semipermeable supports. Monolayers were exposed to normoxia (pO
 
2
 
 
 
5 
 
147 Torr)
or hypoxia (pO
 
2 
 
5
 
 
 
Torr) for 24 h (48 for A549 cells) at 37
 
8
 
C. Paracellular permeability of fluoresceinated dextran (40 kD, 70 kD for A549 cells) was
assessed over a 60-min period and flux was calculated from a standard curve. Results represent mean and SEM from at least three separate experiments.
Figure 1. ITF induction of hypoxia. Confluent Caco-2 epithelial
monolayers were exposed to indicated periods of ambient hypoxia (pO2 5
20 Torr) or normoxia (pO2 5 147 Torr). In a, total RNA was isolated
and examined for ITF transcript by RT-PCR. b-Actin transcript was
used as an internal control. In b, Caco-2 cells were pretreated with vehi-
cle or actinomycin D (Act. D) before 24 h of hypoxia or normoxia. Total
RNA was isolated and examined for ITF mRNA. In c, soluble superna-
tants derived from monolayers exposed to indicated periods of hypoxia
were examined for ITF content by SDS-PAGE and Western blot analysis. 
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confirm these mRNA observations at the protein level,
Western blot analysis of soluble supernatants confirmed an
increase of secreted ITF protein by 48 h (Fig. 1 b).
 
ITF Production Is HIF-1 Dependent.
 
Prompted by these
results, a search of the cloned ITF gene identified a previ-
ously unappreciated HIF-1
 
a
 
 binding site at positions 
 
2
 
129
to 
 
2
 
122 relative to the transcription start site (17) (DNA
consensus motif 5
 
9
 
-TACGTGGG-3
 
9
 
; reference 6). Conse-
quently, we assessed the induction of HIF-1
 
a
 
 and ITF by
hypoxia. First, we determined whether conditions of hy-
poxia induce HIF-1
 
a
 
 in intestinal epithelia (Fig. 2 a).
Western blot analysis of nuclear lysates derived from hy-
poxic intestinal epithelia Caco-2 cells demonstrated abun-
dant HIF-1
 
a
 
 in nuclei. These data are consistent with pre-
vious studies suggesting that HIF-1
 
a
 
 is expressed in most
cell types during periods of hypoxia (3). Next, we exam-
ined the binding of HIF-1
 
a
 
 to the HRE consensus in the
ITF promoter by EMSA (Fig. 2 b). As can be seen, nuclear
extracts derived from hypoxic, but not normoxic, Caco-2
cells bind to the HIF-1
 
a
 
 consensus of the ITF promoter.
Pretreatment of epithelia with 100 mM CoCl2 for 4 h, con-
ditions that promote nuclear accumulation of HIF-1a (5),
resulted in a similar band shift. Addition of anti–HIF-1a
mAb, but not isotype-matched mAb, resulted in a diminu-
tion of shifted signal, but no obvious supershift consistent
with Ab interference with DNA–protein interaction. Incu-
bation with 100-fold excess unlabeled primer resulted in
complete loss of signal. Collectively, these results indicate
that hypoxia elicits nuclear accumulation of HIF-1a,
which binds to the consensus HRE located within the ITF
promoter.
As proof of principle for this concept, intestinal epithelial
cell lines overexpressing HIF-1a were generated by stable
transfection (Fig. 3 a). As shown in Fig. 3 b, overexpression
of HIF-1a resulted in increased basal expression of ITF and
enhanced hypoxia-elicited induction of ITF. Next, anti-
sense oligonucleotides directed against HIF-1a were used
to block HIF-1a expression (Fig. 3 c) and the influence of
HIF-1a depletion on ITF mRNA induction by hypoxia
was assessed (Fig. 3 d). As can be seen, the directed loss of
HIF-1a resulted in a nearly complete loss of ITF mRNA
expression at 4- and 24-h periods of hypoxia. Control oli-
Figure 2. Parallel induction of
HIF-1 and ITF by hypoxia. Con-
fluent Caco-2 epithelial monolay-
ers were exposed to indicated peri-
ods of ambient hypoxia (pO2 5 20
Torr) or normoxia (pO2 5 147
Torr). In a, nuclear lysates derived
from monolayers exposed to nor-
moxia or hypoxia were examined
for HIF-1a content by SDS-
PAGE Western blot analysis. In b,
interactions between HIF-1a and
the HRE of the ITF promoter
gene were examined by EMSA us-
ing synthetic oligonucleotides and
nuclear lysates derived from cells
exposed to normoxia, 4- or 24-h
hypoxia, or CoCl2 (100 mM for 4 h). Specificity was determined with the use of anti–HIF-1a Ab, anti-CREB Ab (control), or excess (XS) unlabeled
probed. Note diminution of signal in the presence of anti–HIF-1a, but not by anti-CREB Ab.
Figure 3. Induction of ITF is
HIF-1a dependent. (a) Analysis of
HIF-1a in transfected Caco-2 cells.
Shown are mock transfected
(Mock), cells overexpressing HIF-
1a  (HIF), and wild-type (WT)
Caco-2 cells exposed to hypoxia and
examined for HIF-1a expression by
Western blot analysis. In b, ITF ex-
pression was analyzed by RT-PCR
in HIF-1a transfectants and mock
transfectants after exposure to indi-
cated periods of hypoxia. In c, cells
were loaded with antisense or sense
oligonucleotides directed against
HIF-1a as indicated and examined
for HIF-1a mRNA. In d, Caco-2
cells pretreated with sense or anti-
sense oligonucleotides as indicated
were exposed to hypoxia or nor-
moxia, and ITF mRNA expression
was analyzed by RT-PCR.1031 Furuta et al.
gonucleotides generated to the sense strand of HIF-1a did
not influence ITF hypoxia inducibility. Taken together,
these results indicate that hypoxia induces a time-depen-
dent HIF-1a nuclear accumulation and parallel ITF induc-
tion.
ITF Promotes Barrier Function In Vitro and In Vivo.
Given the findings described above, studies were under-
taken to determine whether ITF played a functional role in
maintenance of the epithelial integrity during hypoxia. For
this purpose, Caco-2 monolayers were exposed to hypoxia
in the presence or absence of anti-ITF (Fig. 4 a). Increasing
concentrations of anti-ITF sera (titer z1:100,000), but not
isotype-matched antisera, resulted in a dose-dependent in-
crease in epithelial permeability in response to hypoxia (no
Ab versus anti–human [h] ITF at 1:100 dilution; P ,
0.001). These results demonstrate that ITF participates in
the maintenance of barrier function during hypoxia. Fur-
ther evidence in support of ITF as a barrier-protective
agent were provided by addition of recombinant hITF to
hypoxia-sensitive cells. Monolayers of endothelial cells
(which respond to hypoxia with increase paracellular per-
meability, Table I) were used to define this principle. As
shown in Fig. 4 b, addition of hITF to confluent endothe-
lial cells during conditions of hypoxia resulted in a concen-
tration-dependent protection against barrier disruption (no
hITF versus 1 mg/ml hITF; P , 0.01). These data provide
direct evidence for a key role of ITF protein in barrier pro-
tection and suggest that ITF’s functional action may be in-
dependent of the cell type, as illustrated here by the vascu-
lar endothelia.
To define the role of hypoxia-elicited ITF on mucosal
barrier in vivo, intestinal permeability was examined in
wild-type and ITF null mice (21) during 4-h exposure to
ambient hypoxia (8% O2). Under such conditions, in-
creases in both ITF mRNA (Fig. 5 a) and protein (Fig. 5 b)
were induced in tissues derived from wild-type animals
subjected to hypoxia. As shown in Fig. 5 c, upon exposure
to hypoxia, ITF null mice exhibited a significantly greater
increase in intestinal permeability to FITC-dextran (4 kD)
when compared with wild-type mice (ITF knockout ver-
sus wild-type exposed to hypoxia; P , 0.01). Interestingly,
no histologically evident lesions were observed in the co-
lonic mucosa with 4-h exposure to hypoxia (representative
section from wild-type and ITF null animals are shown in
Fig. 5 d). Longer periods of time in hypoxia did not signif-
icantly increase intestinal permeability beyond the 4-h time
point. For example, intestinal permeability of wild-type an-
imals subjected to hypoxia for 18 h (3.3 6 1.2-fold increase
in permeability, n = 4 animals) were not different than ani-
mals exposed to 4-h hypoxia (4.4 6 1.3-fold increase, n =
19 animals). Moreover, these longer time periods resulted
in an unexpected death in ITF null (four out of six animals
tested) but not wild-type animals (zero out of six animals
tested, data not shown). Interestingly, increased intestinal
permeability was also evident in ITF null mice not exposed
to hypoxia as compared with wild-type (P , 0.05 for ITF
null compared with wild-type exposed to normoxia), con-
sistent with the presumption that ITF may contribute to
the maintenance of intestinal barrier under physiological
conditions.
To further define these principles, wild-type and ITF
null mice were administered recombinant ITF protein (30
mg/kg in PBS with 75% intragastric and 25% rectal infu-
sion) before hypoxia. These studies revealed that adminis-
tration of ITF to normoxic ITF null animals resulted in a
significant decrease in permeability (550 6 40 vs. 320 6 90
ng/ml in the absence and presence of ITF administration,
respectively; n = 4 mice per condition, P , 0.04). ITF add-
back to ITF null mice in hypoxia resulted in a trend to-
ward resolution of increased permeability (1,310 6 310 and
970 6 110 ng/ml in the absence and presence of ITF ad-
ministration; n = 6 mice per condition), however, these re-
sults were not statistically significant (P . 0.05). Similar to
these results, ITF administration to wild-type mice in nor-
Figure 4. Functional role of ITF peptide on barrier function. In a,
Caco-2 cells were grown to electrical confluence on polycarbonate sup-
ports. Anti-ITF immune serum at indicated concentrations or control
anti-CREB (1:100) was added to the apical well of the support. Cells
were exposed to indicated periods of ambient hypoxia (pO2 5 20 Torr)
or normoxia. Transepithelial electrical resistance was measured at 48 h
and indicated as data normalized to untreated control monolayers. 1:100
anti-ITF versus no Ab; ***P , 0.001. (b) The influence of recombinant
ITF protein on permeability changes elicited in human MVEC exposure
to hypoxia. Endothelia were grown to confluence on polycarbonate sup-
ports. Recombinant human ITF at indicated concentrations were applied
to the apical well, and cells were exposed to indicated periods of ambient
hypoxia (pO2 5 20 Torr) or normoxia. Flux of 40-kD FITC-labeled
dextran was used to assess endothelial paracellular permeability. 1 mg/ml
hITF versus no recombinant protein; *P , 0.001.1032 Hypoxia-inducible Factor 1–dependent Induction of Intestinal Trefoil Factor
moxia and hypoxia trended toward resolution of increased
permeability but were not statistically significant (data not
shown).
Discussion
These studies provide the first molecular link between
hypoxia and intestinal epithelial barrier protection. Here,
we identify a previously unappreciated HIF-1a regulated
pathway for induction of ITF. ITF is a small, protease-
resistant peptide that is abundant throughout the mamma-
lian intestinal tract (27, 28). Increased ITF expression has
been observed in proximity to sites of injury in the gas-
trointestinal tract, including peptic ulcers and active inflam-
matory bowel disease (27–29). ITF can promote epithelial
barrier function, protecting against injury, and facilitating
repair after damage occurs irrespective of the nature of the
initial wound. However, specific transcriptional pathways
for ITF induction are not well understood (30).
The hypoxia-dependent production of ITF represents a
novel, innate protective mechanism that may guard the im-
munologic components of the lamina propria from expo-
sure to pathogenic luminal bacteria, antigens, and toxins
during episodes of diminished oxygen delivery. Accumu-
lating evidence suggests a variety of physiological roles for
ITF (28), however, molecular mechanisms regulating ITF
expression have not been studied in detail. Rather, the sig-
naling pathways activated by the addition of exogenous
ITF have been more closely examined and include the in-
activation of extracellular signal regulatory kinase, regulated
expression of a- and b-catenin, and transactivation of the
epidermal growth factor receptor (31–33). Recent work
has delineated that ITF can elicit distinct signaling pathways
for epithelial restitution and inhibition of apoptosis, the lat-
ter of which involves activation of mitogen-activated pro-
tein kinase pathways independent of epidermal growth fac-
tor receptor phosphorylation (33). Important for the
present studies, these same extracellular signal regulatory
kinase pathways were recently demonstrated to critically
function in the development of intestinal epithelial barrier
function through regulated expression of claudin-2 and or-
ganization of membrane proteins within the tight junction
(34). Thus, it is likely that ITF-specific, extracellular signal-
ing pathways regulate epithelial barrier under these defined
conditions.
At the tissue and cellular level, an array of genes pivotal
to survival in low oxygen states are activated (4, 35–37).
Original studies of hypoxia-induced EPO production con-
centrated on the regulation of gene transcription. Se-
quences from the EPO promoter were isolated and
identified as a heterodimer with independently regulated
subunits termed HIF-1, a member of the rapidly growing
per-ARNT-sim family of basic helix-loop-helix transcrip-
tion factors (5, 6). HIF-1 exists as an ab heterodimer, the
activation of which is dependent on stabilization of an O2-
dependent degradation domain of the a subunit by the
ubiquitin–proteasome pathway (7). Although not certain,
HIF-1 appears to reside in the cytoplasm of normoxic cells,
and like a number of other transcription factors (e.g., nu-
clear factor kB, b-catenin), HIF-1 translocates to the nu-
cleus to form a functional complex (38, 39). Binding of
HIF-1 to consensus domains in the EPO enhancer results
in the transcriptional induction of HIF-1–bearing gene
promoters (4). Subsequently, it was determined that HIF-1
is widely expressed and that consensus HIF-1–binding se-
quences exist in a number of genes other than EPO and are
termed HRE (4). Of note on this accord, we did not pre-
cisely map the ITF HRE. Attempts to define this site in ex-
act terms were hampered by the complexity of the flanking
region around the HIF-1 consensus sequence (data not
shown). For example, the immediate region of the HIF-1
consensus site also contains consensus binding sites for the
transcription factors myeloid zinc finger-1 (MZF1, consen-
sus 59-AGGGGGA-39), GATA-1 (consensus 59-GGG-
GATTCTG-39), GATA-2 (consensus 59-CAGGA-
TAAGG-39), Sp1 (consensus 59-GTGGCAGGGT-39),
MyoD (consensus 39-GCTGTCCACCGG-59), and up-
stream stimulatory factor (USF, consensus 59-CCAC-
Figure 5. Role of ITF in vivo.
ITF null or wild-type Bl6129F1 mice
were gavaged with 60 mg/100 g
body weight of FITC-dextran and
exposed to 4-h ambient hypoxia (8%
O2) or ambient room air. Mice were
killed, colonic tissue harvested for
RNA (a), Western blot analysis (b),
histologic analysis original magnifica-
tion: 310 (d), and serum FITC-dex-
tran was quantified as a measure of
intestinal permeability (c). *P , 0.05;
**P , 0.01.1033 Furuta et al.
CTGT-39). Important in this regard, at least three of these
transcription factors (GATA-1, GATA-2, and MyoD) have
been recently implicated in either induction or repression
of genes in hypoxia (40–43). Therefore, it is possible that
regulation of the ITF gene at this site could be an interplay
of positive and negative signaling pathways, and given this
complexity, more work will be necessary to define the ex-
act details of this HRE.
Our results suggest that ITF may represent a potential
novel therapeutic approach for a variety of diseases associ-
ated with mucosal hypoxia and altered epithelial barrier
function, including inflammatory bowel disease, necrotiz-
ing enterocolitis, and ischemic colitis (44). In addition,
these results suggest that a receptor/binding site for ITF
may be present at sites other than the gastrointestinal tract,
such as the endothelium. Thus, the protective effect of ITF
on the hypoxia-induced decline in endothelial permeability
suggests that ITF may have even broader therapeutic rele-
vance in conditions of vascular leakiness such as septic
shock. Although it is unknown whether ITF would func-
tion alone in these responses, it is possible, as previously
proposed, that ITF acts in concert with and complemen-
tary to other protective growth factors and cytokines resi-
dent at sites of tissue damage (29). Efforts to better under-
stand ITF signaling pathways and to identify other
hypoxia-elicited protective elements could provide future
focus for the development of novel treatments.
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